ALERZO
6.10.2021 14:52:08 CEST | Business Wire | Press release
Alerzo, one of the fastest growing B2B startups in Nigeria, announced today that its annualized September transaction volume exceeded US$155 million, growing more than fivefold since the beginning of 2021.
Since the company’s Series A fundraising this summer, Alerzo’s B2B marketplace has more than doubled in revenue and has built a payments business that now processes more than 400,000 transactions each month.
Adewale Opaleye (“Ade”) founded Alerzo in Ibadan, Nigeria’s third-largest city, in 2019. The company provides more than 150,000 informal retail stores—more than 90% of which are operated by women—with free same-day delivery, cashless payments and a portfolio of other digital services that enhance store profitability while simplifying owners’ lives.
“I started Alerzo to help my mom, a single mother who ran two informal retail stores to support me and my three siblings. Before Alerzo, she had to close her shop and travel for hours to buy inventory to stay in business,” said Opaleye, who studied physics in Nigeria and computer science in China. “Women are often victims of theft because street boys know retail store operators often carry cash. I wanted to apply what I learned in China to make life better for working mothers in Nigeria.”
This summer Alerzo acquired Shago Payments to accelerate its transformation from a B2B marketplace to an all-in-one technology platform. Shago, founded by payments industry veteran Sabastine Enechi, accelerates Alerzo’s push into digital products and financial services. With Shago’s integration into AlerzoPay, the company’s payments arm, Alerzo now provides informal retail stores with a portfolio of new digital services such as mobile airtime top-up; bill payments and peer-to-peer transfers.
Santie Botha, chairman of Capitec Bank (South Africa), recently joined Alerzo’s board as the lead independent director. “I joined Alerzo’s board because I was inspired by Ade’s life story and share Alerzo’s commitment to empower working women in Africa,” Botha said.
Iyinoluwa Aboyeji, the co-founder of Flutterwave and Andela and a member of Alerzo’s advisory board said: "Most businesses talk a good game about financial and economic inclusion but then proceed to focus their businesses on commercially savvy mega cities like Lagos or Nairobi. Alerzo's focus on excluded but commercially viable commerce communities in smaller cities like Ibadan is exemplary and visionary. I'm inspired by their focus on communities that are truly excluded.”
In addition to Aboyeji, Alerzo’s advisory board includes senior executives who have worked at KKR, Facebook, Wellington Management and Galaxy Digital, among others.
Christina Sass, one of Alerzo’s investors and an Andela cofounder, said: “Alerzo is one of the rare social enterprises where an obvious and powerful social mission succeeds in tandem with the company's financial performance.”
In September, Alerzo expanded its operations to the Middle Belt and Northern regions of Nigeria, and now operates in Abuja and Kano. The Company plans to serve most of Nigeria before the end of next year.
About Alerzo
Alerzo, headquartered in Singapore and Ibadan, Nigeria, is an all-in-one technology and services platform that transforms how Nigeria’s informal retail stores operate. With Alerzo, retailers can order stock, have it delivered quickly, receive and make cashless payments, track store profitability better, and facilitate a portfolio of digital services including airtime purchases, bill payments, and peer-to-peer transfers. Visit us at www.alerzo.com or follow us on LinkedIn , and to learn more about Alerzo please contact us at IR@alerzo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005148/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
